Flipkart, Fortis co-founders to invest in Medtech startup Wrig Nanosystems

Published On 2015-07-30 10:11 GMT   |   Update On 2015-07-30 10:11 GMT

Wrig Nanosystems has managed to capture the interest of Sachin and Binny Bansal, Malvinder and Shivinder Singh (former Ranbaxy and Fortis promoters), Gurpreet Singh (Round Glass Partners) and othersWrig Nanosystems, a medical technology startup company which develops and markets a hemoglobin measurement device, has attracted financial interest from different investors in the product. The...

Login or Register to read the full article
Wrig Nanosystems has managed to capture the interest of Sachin and Binny Bansal, Malvinder and Shivinder Singh (former Ranbaxy and Fortis promoters), Gurpreet Singh (Round Glass Partners) and others

Wrig Nanosystems, a medical technology startup company which develops and markets a hemoglobin measurement device, has attracted financial interest from different investors in the product. The company has made an investment of up to 15 cr to commercialise and further develop the product and Avendus Wealth Management acted as the advisor to Wrig on this deal.

The list of investors includes Flipkart co-founders Sachin and Binny Bansal, Malvinder and Shivinder Singh (former Ranbaxy and Fortis promoters), Gurpreet Singh (Round Glass Partners) and others.

Founded in 2009 by Ambar Srivastava, Wrig Nanosystems has names its product as TrueHb Hemometer. The device costs between R3,000 – R12,000, with 4000 units being sold till now, since its launch in December last year. The list of buyers includes some renowned healthcare chains like Max and Fortis, besides the governments of Madhya Pradesh, Uttar Pradesh, Uttarakhand and Himachal Pradesh, who uses it for their public health initiatives.

 

 

 
Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News